Swayampakula Ramakanth, an analyst from H.C. Wainwright, maintained the Buy rating on Mediwound. The associated price target remains the same with $31.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Swayampakula Ramakanth’s rating is based on several promising developments within MediWound. The company has shown robust demand for its NexoBrid product, with no inventory remaining as all manufactured products are being utilized. This strong demand supports the belief that the revenue guidance for 2025 is conservative. Additionally, the anticipated approval of the expanded manufacturing facility by EMA and FDA in 2026 could significantly boost NexoBrid sales by 2027.
Furthermore, MediWound’s receipt of substantial funding from the Department of Defense and the ongoing efforts to secure additional grants through a Request for Proposal could enhance procurement revenues and support the development of a room temperature-stable formulation of NexoBrid. The company’s EscharEx product is also progressing well, with a Phase 3 study underway and expected to reach the market by the third quarter of 2028. These factors collectively contribute to Ramakanth’s Buy rating for MediWound.
According to TipRanks, Ramakanth is a 4-star analyst with an average return of 8.7% and a 40.00% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Unicycive Therapeutics, Corcept Therapeutics, and Mediwound.
In another report released yesterday, TD Cowen also maintained a Buy rating on the stock with a $25.00 price target.